BioPharma Dive July 8, 2024
Acquiring Apeiron will give Ligand royalty rights to a cancer drug, while negative study data for Roche’s tiragoluamb have further dimmed expectations for TIGIT as a cancer drug target.
Today, a brief rundown of news from Ligand Pharmaceuticals and Aerovate Therapeutics, as well as updates from Roche and CSL Behring that you may have missed.
Ligand Pharmaceuticals will pay $100 million to acquire the private Austria-based Apeiron Biologics. The deal hands Ligand royalty rights to sales of Qarziba, an approved treatment for high-risk glioblastoma that Apeiron co-developed and later licensed to Eusa Pharma outside of China. Recordati, which acquired Eusa in 2022, now sells the drug. Ligand is also committing to investing up to $4 million in a private spinout...
Today's Sponsors
Today's Sponsor